A Phase I, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of V212 in Healthy Adults.
Phase of Trial: Phase I
Latest Information Update: 31 Oct 2013
At a glance
- Drugs V 212 (Primary)
- Indications Herpes zoster
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Merck & Co
- 18 Nov 2009 Planned end date changed from 1 Feb 2010 to 1 Feb 2009 as reported by ClinicalTrials.gov.
- 04 Nov 2009 Planned number of patients changed from 160 to 288 as reported by ClinicalTrials.gov.
- 14 Oct 2009 Planned number of patients changed from 288 to 160 as reported by ClinicalTrials.gov.